PROTHENA CORP PUBLIC LTD CO (PRTA) earnings date
Feb 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | after close | 50 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | after close | 35 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 20, 2025 | after close | 51 | 8-K |
What they guided beta
| Q3 FY2026 | "Both programs are in Phase 3 clinical trials, PARAISO (prasinezumab) and CLEOPATTRA (coramitug), with primary completions expected in 2029,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena." exhibit |
| Q3 FY2026 | "“Bristol Myers Squibb continues to conduct the Phase 2 TargetTau-1 trial evaluating moponetug in patients with early Alzheimer’s disease, with data readout expected in the first half of 2027." exhibit |
| Q3 FY2026 | "Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants for a minimum of 104 weeks with early-stage Parkinson's disease on stable symptomatic monotherapy with levodopa; primary completion expected in 2029 (NCT07174310)" exhibit |
| Q3 FY2026 | "Novo is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)" exhibit |
| Q3 FY2026 | "Open-label study ongoing to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)" exhibit |
| Q2 FY2026 | "Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash" exhibit |
| Q2 FY2026 | "Roche is currently evaluating prasinezumab in the Phase 3 PARAISO trial, with primary completion expected in 2029,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena." exhibit |
| Q2 FY2026 | "“In addition, Novo Nordisk is conducting the Phase 3 CLEOPATTRA clinical trial evaluating coramitug in patients with ATTR amyloidosis with cardiomyopathy, with primary completion expected in 2029." exhibit |
| Q2 FY2026 | "We also expect our partner Bristol Myers Squibb to complete the ongoing Phase 2 TargetTau-1 clinical trial evaluating moponetug (BMS-986446) in patients with early Alzheimer’s disease in the first half of 2027." exhibit |
| Q2 FY2026 | "Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants with early-stage Parkinson's disease; primary completion expected in 2029 (NCT07174310)" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PRTA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PRTA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PRTA/"><img src="https://veritasdata.dev/embed/PRTA.svg" alt="PRTA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PRTA/)
Script
<script async src="https://veritasdata.dev/embed/PRTA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PRTA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.